Abstract:BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available. BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available.

Effects of Silencing Connective Tissue Growth Factor on Rat Transforming Growth Factor Beta/smads Signal

Effect of silencing connective tissue growth factor by small interfering RNA on culture-activated rat hepatic stellate cells

RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production.

Inhibition of Connective Tissue Growth Factor by Sirna Prevents Liver Fibrosis in Rats.

[Effect of silencing connective tissue growth factor on the liver fibrosis in rats].

[Effect of Silencing Connective Tissue Growth Factor on Rat Liver Fibrosis and the Accumulation of Extracellular Matrix].

Effects of siRNA targeting transforming growth factorβ1 on biological characteristics of rat hepatic satellite cells

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Effect of Small Interfering RNA Targeting Connective Tissue Growth Factor on the Synthesis and Secretion of Extracellular Matrix in Hepatic Stellate Cells

[Effects of blocking two sites of transforming growth factor-β/Smads signaling on the formation of scar-related proteins in human skin fibroblasts].

Design,synthesis and Activity Evaluation of Small Interfering RNA Targeting Connective Tissue Growth Factor

Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.

Transforming Growth Factor-1 Downregulation of Smad 1 Gene Expression in Rat Hepatic Stellate Cells

Inhibition Effect of Chemically Synthetic Sirna on Connective Tissue Growth Factor in HSC

Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo

Small Interfering RNA Targeting Connective Tissue Growth Factor Prevents Rats Liver Fibrosis

722. Silencing of Transforming Growth Factor-β Receptor II by RNA Interference Suppresses Extracellular Matrix Production in Rat Hepatic Stellate Cells

Effect of Shrna-Mediated Silencing of CTGF and TIMP-1 on Mrna Expression of CTGF, TIMP-1, and PCI and Secretion of Extracellular Matrix in Rat Hepatic Stellate Cells

Effects of CTGF on Kupffer Cells Induced Activation of Hepatic Stellate Cells

Effect of Smad4 siRNA on transforming growth factor-beta-induced-type Ⅰ collagen expression